Skip to main content
SpringerLink
Log in

Diclofenac MACE risk versus older and newer COX-2 inhibitors

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Schmidt M, et al. Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials Drug Safety : 3 Aug 2022. Available from: URL: https://doi.org/10.1007/s40264-022-01211-1

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Diclofenac MACE risk versus older and newer COX-2 inhibitors. Reactions Weekly 1918, 10 (2022). https://doi.org/10.1007/s40278-022-20467-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-20467-8

Search

Navigation